Clinical efficacy and safety outcomes of bempedoic acid: An updated systematic review and meta-analysis after CLEAR Outcomes trial

•We performed a meta-analysis to assess the clinical efficacy and safety outcomes of bempedoic acid.•We found that bempedoic acid is an alternative or add-on therapy to reduce cardiovascular events in selective patients.•Bempedoic acid reduced non-fatal myocardial infarction, hospitalization for uns...

Full description

Saved in:
Bibliographic Details
Published in:Health sciences review (Oxford, England) England), 2023-12, Vol.9, p.100116, Article 100116
Main Authors: Bhandari, Amit, Oli, Prakash Raj, Shrestha, Dhan Bahadur, Dawadi, Sagun, Pathak, Bishnu Deep, Bhandari, Manoj, Sedhai, Yub Raj, Basnet, Bibhusan, Regmi, Laxmi, Singh, Aniruddha, Patel, Nimesh K.
Format: Article
Language:English
Subjects:
Atherosclerotic cardiovascular diseases
Bempedoic acid
Hyperlipidemia
Statin
Statin intolerance
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•We performed a meta-analysis to assess the clinical efficacy and safety outcomes of bempedoic acid.•We found that bempedoic acid is an alternative or add-on therapy to reduce cardiovascular events in selective patients.•Bempedoic acid reduced non-fatal myocardial infarction, hospitalization for unstable angina and coronary revascularization significantly.•Further trials may shed more light on the bempedoic acid. Statins are the cornerstone therapy for primary or secondary prevention of atherosclerotic cardiovascular disease (ASCVD). However, a significant portion of patients are intolerant to statin or show inadequate lipid-lowering. Bempedoic acid (BA) has been shown to decrease low-density lipoprotein cholesterol (LDL-C) in clinical trials. However, the evidence on the effect of BA on clinical cardiovascular outcomes was limited until the CLEAR Outcomes trial. Thus, to fully appraise the available data, we performed this meta-analysis. PubMed, Pubmed Central, Embase, and Scopus databases were searched for relevant articles published before May 1, 2023. Pertinent data from the included studies were extracted and analyzed using RevMan v5.4. Out of 2209 studies evaluated, five randomized control trials with 17,384 patients with established ASCVD or at high risk of ASCVD were included for analysis. The BA therapy reduced major adverse cardiovascular events (OR 0.85, CI 0.77-0.93;
ISSN:2772-6320
2772-6320
DOI:10.1016/j.hsr.2023.100116